title: Cancer cachexia: medical management.
abstract: BACKGROUND
  Cachexia is a complex metabolic syndrome associated with many chronic or end-stage diseases, especially cancer, and is characterized by loss of muscle with or without loss of fat mass. The management of cachexia is a complex challenge that should address the different causes underlying this clinical event with an integrated or multimodal treatment approach targeting the different factors involved in its pathophysiology.
  
  
  METHODS
  The purpose of this article was to review the current medical treatment of cancer-related cachexia, in particular focusing on combination therapy and ongoing research.
  
  
  RESULTS
  Among the treatments proposed in the literature for cancer-related cachexia, some proved to be ineffective, namely, cyproheptadine, hydrazine, metoclopramide, and pentoxifylline. Among effective treatments, progestagens are currently considered the best available treatment option for cancer-related cachexia, and they are the only drugs approved in Europe. Drugs with a strong rationale that have failed or have not shown univocal results in clinical trials so far include eicosapentaenoic acid, cannabinoids, bortezomib, and anti-TNF-alpha MoAb. Several emerging drugs have shown promising results but are still under clinical investigation (thalidomide, selective cox-2 inhibitors, ghrelin mimetics, insulin, oxandrolone, and olanzapine).
  
  
  CONCLUSIONS
  To date, despite several years of co-ordinated efforts in basic and clinical research, practice guidelines for the prevention and treatment of cancer-related muscle wasting are lacking, mainly because of the multifactorial pathogenesis of the syndrome. From all the data presented, one can speculate that one single therapy may not be completely successful in the treatment of cachexia. From this point of view, treatments involving different combinations are more likely to be successful.
authors.affiliation: Department of Medical Oncology, University of Cagliari, Cagliari, Italy. mantovan@medicina.unica.it
authors.forename: Giovanni
authors.initials: G
authors.lastname: Mantovani
authors.forename: Clelia
authors.initials: C
authors.lastname: Madeddu
mesh_terms: D002100:Cachexia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D004359:Drug Therapy, Combination / Q000379:methods* / Q000639:trends; D006801:Humans; D009369:Neoplasms / Q000150:complications*
references.citation: J Exp Ther Oncol. 2004 Apr;4(1):69-78
references.pmid: 15255293
references.citation: J Clin Oncol. 2006 Jul 20;24(21):3401-7
references.pmid: 16849754
references.citation: Clin Cancer Res. 2003 Oct 15;9(13):4653-65
references.pmid: 14581334
references.citation: Cancer. 1992 Mar 1;69(5):1268-74
references.pmid: 1739926
references.citation: Int J Clin Lab Res. 1995;25(3):135-41
references.pmid: 8562975
references.citation: Br J Cancer. 1994 May;69(5):826-32
references.pmid: 8180010
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1030-4
references.pmid: 16702388
references.citation: Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004310
references.pmid: 15846706
references.citation: J Clin Endocrinol Metab. 2004 Jun;89(6):2832-6
references.pmid: 15181065
references.citation: Am J Pathol. 2005 Apr;166(4):1131-41
references.pmid: 15793293
references.citation: J Clin Oncol. 2002 Jan 15;20(2):567-73
references.pmid: 11786587
references.citation: BioDrugs. 2005;19(3):179-87
references.pmid: 15984902
references.citation: Nutr Cancer. 2007;59(1):14-20
references.pmid: 17927497
references.citation: Drugs. 2001;61(4):499-514
references.pmid: 11324680
references.citation: Nutrition. 2008 Sep;24(9):806-14
references.pmid: 18725076
references.citation: FEBS Lett. 2004 Jul 2;569(1-3):201-6
references.pmid: 15225634
references.citation: Support Care Cancer. 2008 Mar;16(3):229-34
references.pmid: 18071761
references.citation: Br Med J (Clin Res Ed). 1984 Jan 7;288(6410):27
references.pmid: 6418303
references.citation: Clin Cancer Res. 2007 May 1;13(9):2699-706
references.pmid: 17473202
references.citation: Curr Opin Oncol. 2006 Jul;18(4):335-40
references.pmid: 16721127
references.citation: Curr Opin Clin Nutr Metab Care. 2005 Jul;8(4):408-14
references.pmid: 15930966
references.citation: Mol Psychiatry. 2000 Nov;5(6):616-32
references.pmid: 11126392
references.citation: Free Radic Res. 2003 Feb;37(2):213-23
references.pmid: 12653210
references.citation: Drug Discov Today. 2008 Jan;13(1-2):73-8
references.pmid: 18190867
references.citation: Br J Cancer. 1999 Sep;81(1):80-6
references.pmid: 10487616
references.citation: J Clin Oncol. 1999 Oct;17(10):3299-306
references.pmid: 10506633
references.citation: Support Care Cancer. 2005 Jun;13(6):381-6
references.pmid: 15759136
references.citation: Br J Cancer. 2009 Mar 10;100(5):713-22
references.pmid: 19259092
references.citation: J Clin Oncol. 2006 Jul 20;24(21):3394-400
references.pmid: 16849753
references.citation: Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1651-9
references.pmid: 15466983
references.citation: Gut. 2003 Oct;52(10):1479-86
references.pmid: 12970142
references.citation: Biochem J. 2007 Oct 1;407(1):113-20
references.pmid: 17623010
references.citation: Eur J Cancer. 1997 Apr;33(4):602-7
references.pmid: 9274442
references.citation: Clin Nutr. 2008 Dec;27(6):793-9
references.pmid: 18718696
references.citation: Cancer. 1998 Feb 1;82(3):553-60
references.pmid: 9452274
references.citation: Cancer. 1974 Jun;33(6):1607-9
references.pmid: 4135151
references.citation: Clin Cancer Res. 2007 Mar 1;13(5):1356-61
references.pmid: 17332276
references.citation: J Clin Oncol. 2004 Jun 15;22(12):2469-76
references.pmid: 15197210
references.citation: J Natl Cancer Inst. 1990 Jul 4;82(13):1127-32
references.pmid: 2193166
references.citation: Ann Oncol. 1997 Mar;8(3):277-83
references.pmid: 9137798
references.citation: Cancer Res. 1991 Nov 15;51(22):6089-93
references.pmid: 1657378
references.citation: J Pain Symptom Manage. 2004 Jan;27(1):85-95
references.pmid: 14711473
references.citation: J Support Oncol. 2008 Jan;6(1):18-25
references.pmid: 18257397
references.citation: J Clin Oncol. 1993 Apr;11(4):762-7
references.pmid: 8478668
references.citation: Clin Nutr. 2007 Aug;26(4):389-99
references.pmid: 17499396
references.citation: Br J Cancer. 2008 Jan 29;98(2):300-8
references.pmid: 18182992
references.citation: Oncol Rep. 2002 Jul-Aug;9(4):887-96
references.pmid: 12066227
references.citation: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD004597
references.pmid: 17253515
references.citation: Cancer Res. 2007 Jul 1;67(13):6512-9
references.pmid: 17616713
references.citation: Cancer. 1990 Sep 15;66(6):1279-82
references.pmid: 2205358
references.citation: Crit Rev Food Sci Nutr. 2003;43(1):89-143
references.pmid: 12587987
references.citation: Gut. 2005 Apr;54(4):540-5
references.pmid: 15753541
references.citation: J Environ Pathol Toxicol Oncol. 2003;22(1):17-28
references.pmid: 12678402
references.citation: J Exp Ther Oncol. 2003 Jul-Aug;3(4):205-19
references.pmid: 14567291
references.citation: J Mol Med (Berl). 2003 Oct;81(10):664-73
references.pmid: 12928788
references.citation: Trends Endocrinol Metab. 2006 Jul;17(5):199-204
references.pmid: 16750633
references.citation: Head Neck. 2008 Jan;30(1):67-74
references.pmid: 17615567
references.citation: Nutrition. 2008 Apr;24(4):305-13
references.pmid: 18262758
references.citation: Eur J Cancer. 2008 May;44(8):1124-32
references.pmid: 18375115